Book contents
- Frontmatter
- Contents
- Contributors
- Foreword
- Preface
- Part I General concepts of PET and PET/CT imaging
- Part II Oncologic applications
- Chapter 5 Brain
- Chapter 6 Head, neck, and thyroid
- Chapter 7 Lung and pleura
- Chapter 8 Esophagus
- Chapter 9 Gastrointestinal tract
- Chapter 10 Pancreas and liver
- Chapter 11 Breast
- Chapter 12 Cervix, uterus, and ovary
- Chapter 13 Lymphoma
- Chapter 14 Melanoma
- Chapter 15 Bone
- Chapter 16 Pediatric oncology
- Chapter 17 Malignancy of unknown origin
- Chapter 18 Sarcoma
- Chapter 19 Methodological aspects of therapeutic response evaluation with FDG-PET
- Chapter 20 FDG-PET/CT-guided interventional procedures in oncologic diagnosis
- Index
- References
Chapter 10 - Pancreas and liver
from Part II - Oncologic applications
Published online by Cambridge University Press: 05 September 2012
- Frontmatter
- Contents
- Contributors
- Foreword
- Preface
- Part I General concepts of PET and PET/CT imaging
- Part II Oncologic applications
- Chapter 5 Brain
- Chapter 6 Head, neck, and thyroid
- Chapter 7 Lung and pleura
- Chapter 8 Esophagus
- Chapter 9 Gastrointestinal tract
- Chapter 10 Pancreas and liver
- Chapter 11 Breast
- Chapter 12 Cervix, uterus, and ovary
- Chapter 13 Lymphoma
- Chapter 14 Melanoma
- Chapter 15 Bone
- Chapter 16 Pediatric oncology
- Chapter 17 Malignancy of unknown origin
- Chapter 18 Sarcoma
- Chapter 19 Methodological aspects of therapeutic response evaluation with FDG-PET
- Chapter 20 FDG-PET/CT-guided interventional procedures in oncologic diagnosis
- Index
- References
Summary
Pancreatic cancer
General concepts and epidemiology
According to the American Cancer Society, it is estimated that 43,140 Americans will be diagnosed with pancreatic carcinoma in 2010 with an estimated 36,800 deaths. This represents the 10th most commonly diagnosed malignancy, but the fourth leading cause of cancer-related death (1). Pancreatic adenocarcinoma is one of the most lethal of all malignancies with a 1-year survival of 20–25% and a 5-year survival rate of approximately 5% (2). Survival for pancreatic adenocarcinoma remains dismally low despite advances in diagnostic and therapeutic development over the past several years. Currently, the only potentially curative treatment is surgical resection, which is only an option for 15–20% of patients. For those who are surgical candidates, 5-year survival following pancreaticoduodenectomy remains low at 25–30% in patients with no nodal involvement.
Tumors arising from the pancreas can be exocrine or endocrine in origin. The most common type of exocrine tumor of the pancreas is ductal adenocarcinoma. Adenosquamous, squamous, and giant cell tumors are much less common. Acinar cell carcinomas are rare and have a similar prognosis as for ductal carcinoma. Pancreatic neuroendocrine tumors such as insulinoma, glucagonoma, and gastrinoma are uncommon and are often associated with other endocrine abnormalities. Pancreatic endocrine tumors are usually slow growing and are typically found in the body or tail of the pancreas. Benign cysts, pseudocysts, and cystadenomas may occur within the pancreas, although malignant cystic neoplasms may also occur.
- Type
- Chapter
- Information
- A Case-Based Approach to PET/CT in Oncology , pp. 242 - 266Publisher: Cambridge University PressPrint publication year: 2012